Gilteritinib is an FLT3 inhibitor. It’s mainly used to treat AML patients who’ve relapsed or are refractory, and who have FLT3 mutations. FLT3 is the active ingredient.
It works by blocking FLT3 kinase, which in turn stops leukemia cells from growing. Gilteritinib is available as a film-coated tablet, with each one containing 40 milligrams. The suggested dose is 120 mg, taken once a day, and it’s taken by mouth.
The medication comes in bottles, and each bottle has 90 tablets.
